AVAILABILITY OF INNOVATIVE CARDIOMETABOLIC MEDICINES IN LATIN AMERICA: IMPLICATIONS FOR HEALTH SYSTEM EFFICIENCY AND ACCESS
Author(s)
Andre Ballalai, BSc1, OSCAR COURTNEY, BSc2, Francisca Rodriguez, MD3, Silvana Lay Ma, Eng., MBA4, Diego F. Guarin, MPH, MSc, MD4;
1IQVIA, New York, NY, USA, 2IQVIA, MEXICO, Mexico, 3cif chile, santiago, Chile, 4FIFARMA, Mexico, Mexico
1IQVIA, New York, NY, USA, 2IQVIA, MEXICO, Mexico, 3cif chile, santiago, Chile, 4FIFARMA, Mexico, Mexico
OBJECTIVES: To assess access to innovative cardiometabolic medicines across Latin America and provide evidence to support value-based health system decision-making.
METHODS: Thirty-eight innovative cardiometabolic medicines approved globally between 2014 and 2024 were analyzed across ten countries. Availability and time-to-access definitions were standardized. Extended availability included full, limited, and private access. Data were collected in collaboration with national associations, research-based companies, and public sources. Descriptive quantitative analyses were conducted.
RESULTS: Average extended availability reached 23%, ranging from 8% in Brazil to 39% in Argentina. Time to availability varied between 22 and 43 months. Due to the absence of comparable international datasets, analyses focused on regional performance.
CONCLUSIONS: Despite the growing burden of cardiometabolic diseases, access to innovative treatments remains delayed and uneven. Addressing regulatory, HTA, and budgetary barriers is critical to improve system efficiency and accelerate patient access to high-value therapies.
METHODS: Thirty-eight innovative cardiometabolic medicines approved globally between 2014 and 2024 were analyzed across ten countries. Availability and time-to-access definitions were standardized. Extended availability included full, limited, and private access. Data were collected in collaboration with national associations, research-based companies, and public sources. Descriptive quantitative analyses were conducted.
RESULTS: Average extended availability reached 23%, ranging from 8% in Brazil to 39% in Argentina. Time to availability varied between 22 and 43 months. Due to the absence of comparable international datasets, analyses focused on regional performance.
CONCLUSIONS: Despite the growing burden of cardiometabolic diseases, access to innovative treatments remains delayed and uneven. Addressing regulatory, HTA, and budgetary barriers is critical to improve system efficiency and accelerate patient access to high-value therapies.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HPR1
Topic
Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity, Reimbursement & Access Policy
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)